• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Ministry of Health and partners disclose recommendations to overcome barriers to access to diagnosis and treatment for Chagas Disease in Colombia

Bogotá, Colombia — 23 Apr 2015

At an international seminar that gathered international and Colombian experts in Bogotá, capital, representatives of the General System of Social Security in Health, knowledge management, civil society and international cooperation agreed upon necessary measures to rebuild and reinforce proposals to guarantee the right to health on affected areas, including a model project for the treatment of Chagas disease, both at regional and national levels.
[Español] [Português]

A proposal of a model project that can be feasible at national level, but also sustainable and replicable in other countries of the region, was one of the outcomes of the seminar “Towards the Elimination of Barriers to Diagnosis and Treatment Access of Chagas disease in Colombia” that took place in Bogotá, capital of Colombia. The meeting was also the platform for the production of a document that gathers recommendations, such as a roadmap for the country with special emphasis primary health level attention to patients – including diagnosis and treatment – as well as health promotion and prevention.

The roadmap also includes the request of new guidelines for treatment as part of a new medical protocol for Chagas disease, the acceleration of the regulatory process for the registration of the medicine in the country, as well as a Plan for Information, Education and Communication.

“The Ministry of Health and Social Protection of Colombia will support all initiatives and to act as a leader  of  the improvement of access to diagnosis and treatment of Chagas disease in the Latin American region”, said Alejandro Gaviria Uribe, Minister of Health and Social Protection. “We know that Chagas is related to housing conditions and poverty, for which it requires coordinated actions within different sectors to reduce the risk of infection. This disease brings up equity challenges that are within the frame of the National Development Plan”, he added.

Currently, it is estimated that in Colombia there are 4.800.000 people under risk of infection and 437.000 estimated total cases. Nevertheless, in seven years there have been screened 53.700 people not including those identified in blood banks, which diagnostic approximately 2.000 new cases a year, as per data of 2010 of the World Health Organization. From this total, less than 1.000 have received medicine treatment, according to the National Health Institute of Colombia.

Chagas disease has been defined as one of the priorities of the Ten Year Plan for Public Health in Colombia, with goals such as the reduction of deaths and vector control.

The seminar was organized by the Ministry of Health and Social Protection, The National Health Institute and the Red Chagas of Colombia, as well as the Drugs for Neglected Diseases Initiative (DNDi) on April 22 and 23 in Bogota. Fifty people directly or indirectly involved with Chagas disease attended the seminar, both from the governmental and non-governmental sectors, as well as people affected by the disease.

About Chagas Disease
Chagas disease or American Tripanosomiasis is an infection caused by the parasite Trypanosoma cruzi and is named after its discoverer, the Brazilian Doctor Carlos Chagas.

There are four main forms of transmission: by the bite of the vector insect (kissing bug or “chinche” or “pito” in Spanish) infected with the parasite; by contaminated blood transfusion or organ transplant; by transmission mother-son during pregnancy, if the woman is infected; or by oral infection.

Some of the symptoms are fatigue, headache, loss of appetite, diarrhea, vomits, swollen glands and welling of one eye. It can also present symptoms of heart problems.

Presently there are two medicines for the treatment of Chagas: benznidazole and nifurtimox. For children under one year old, the treatment achieves full recovery. Both in children as well as in youths, the treatment has less side effects than in adults. In adults the treatment can avoid the progression of the disease and heart complications.

Partnership Registration & access Chagas disease Colombia Latin America

Read, watch, share

Loading...
Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

Woman walking in a laboratory
Press releases
23 Apr 2025

DNDi welcomes GHIT support for new project with three Japanese universities to find drug candidates for Chagas disease

Stories
16 Apr 2025

Drug discovery explained: Chagas – How to prove treatments work?

Statements
16 Apr 2025

Statement from the Drugs for Neglected Diseases initiative (DNDi) on the conclusion of WHO Pandemic Agreement negotiations

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License